CYP450 Enzymes and THC Metabolism

THC is broken down primarily by three liver enzymes in the CYP450 family. Genetic variation in these enzymes is one reason people clear cannabis at different rates — and why two people with identical use patterns can have different detection windows.

The Three Enzymes That Matter

CYP2C9 — the primary enzyme responsible for 11-hydroxylation of THC to 11-OH-THC. This is the main clearance pathway.
CYP3A4 — catalyzes minor alternative routes including 8β-hydroxylation.
CYP2C19 — contributes to 11-hydroxylation at lower levels than CYP2C9.

The overall reaction cascade is: Δ9-THC → 11-OH-THC (via CYP2C9 primarily) → THC-COOH → THC-COOH-glucuronide (excreted in urine).

Genetic Variation Affects Clearance

CYP2C9 exists in multiple forms due to single-nucleotide polymorphisms. The two most studied variants are CYP2C9*2 and CYP2C9*3, both of which produce enzymes with reduced activity compared to the wild-type CYP2C9*1. Individuals carrying these variants metabolize THC more slowly.

In one study of 71 oral cannabis users, 44% carried atypical CYP2C9 variants. Poor metabolizers:

Show higher peak plasma THC concentrations
Experience more intense psychoactive effects from a given dose
Have lower plasma THC-COOH concentrations (because less is being produced per unit time)
May have longer overall detection windows due to slower elimination

This is clinically relevant. Genetic polymorphism is one reason the same cannabis dose produces different effects in different people, and it is one reason detection windows vary even among people with identical use patterns.

Drug Interactions

Because CYP2C9 and CYP3A4 metabolize many other drugs, there is potential for interactions:

CYP3A4 inhibitors (some antifungals, grapefruit juice, certain HIV medications, erythromycin) may slow THC clearance
CYP3A4 inducers (rifampin, phenytoin, St. John's Wort) may accelerate clearance
CYP2C9 interactions are less extensively documented for cannabis specifically

In practice, these interactions are rarely large enough to flip a drug test result, but they contribute to individual variation in detection windows.

Evidence Quality Note

Core enzyme roles in THC metabolism are well-established science. The clinical significance of specific genetic polymorphisms is rapidly evolving — newer pharmacogenomic studies are refining our understanding of how much variation these polymorphisms really explain. If you see strong claims about genetic testing for drug test preparation, treat them skeptically; the research is not yet at a point where personal genotyping meaningfully predicts detection window.

Strong Evidence — CYP2C9, CYP3A4, and CYP2C19 roles in THC metabolism are well-established

Moderate Evidence — Clinical significance of specific polymorphisms for drug testing outcomes

Why This Matters for Testing

Two takeaways for people facing drug tests:

There is no universal detection window. The numbers we cite throughout this site are population averages. Individual clearance can be faster or slower depending on genetics, body composition, exercise history, and other factors.
Nothing commercially available can meaningfully speed up CYP450 metabolism. The "detox" industry cannot alter enzyme expression or activity in any clinically significant way. The only evidence-based method is time and abstinence.